• Another Analysis of Trastuzumab for Only 9 Weeks: Not an Option

    16 days ago - By Medscape

    A 9-week course of trastuzumab for low- and intermediate-risk early breast cancer looks possible but is not recommended as a standard of care according to experts.
    Medscape Medical News
    Read more ...

     

  • Hormone-blocking injections reduce early menopause from breast cancer treatment

    16 days ago - By ScienceDaily

    Final results of a clinical trial show continued evidence that women who get injections of the hormone drug goserelin along with standard breast cancer chemotherapy are more likely to become pregnant - without developing negative side effects or shortening their lives.
    Read more ...